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The lipid mediator sphingosine 1-phosphate (S1P) affects cellular functions in most systems. Interest in its 
therapeutic potential has increased following the discovery of its G protein-coupled receptors and the recent 
availability of agents that can be safely administered in humans. Although the role of S1P in bone biology has 
been the focus of much less research than its role in the nervous, cardiovascular and immune systems, it is 
becoming clear that this lipid influences many of the functions, pathways and cell types that play a key role in 
bone maintenance and repair.  Indeed, S1P is implicated in many osteogenesis-related processes including stem 
cell recruitment and subsequent differentiation, differentiation and survival of osteoblasts, and coupling of the 
latter cell type with osteoclasts. In addition, S1P’s role in promoting angiogenesis is well-established. The 
pleiotropic effects of S1P on bone and blood vessels have significant potential therapeutic implications, as 
current therapeutic approaches for critical bone defects show significant limitations. Because of the complex 
effects of S1P on bone, the pharmacology of S1P-like agents and their physico-chemical properties, it is likely 
that therapeutic delivery of S1P agents will offer significant advantages compared to larger molecular weight 
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factors.  Hence, it is important to explore novel methods of utilizing S1P agents therapeutically, and improve 
our understanding of how S1P and its receptors modulate bone physiology and repair. 
Keywords: Bone regeneration, bone defect, osteoblasts, osteoclasts, sphingosine 1-phosphate 
1 Introduction 
The incidence of non-union fractures is relatively low (20 per 100000 cases) (1). However, in severe fractures or 
in limb salvage following bone cancer, the incidence can be many fold higher (2). Current therapeutic options 
for non-union and other critical bone defects, mainly autologous grafts and allografts, suffer from drawbacks of 
both medical and logistical natures (3). There has been much hope that novel treatments based on the use of 
peptide or protein growth factors, mainly in combination with bone grafts or scaffolds, would show clinical 
benefit. Despite showing positive results, these strategies are limited by the need for high doses, as well as 
related ectopic growth (4-6). A potential promising alternative is the manipulation of lower molecular weight, 
non peptidic mediators, such as the bioactive lipid sphingosine 1-phosphate (S1P) (7). 
S1P is the product of sphingosine kinase (SK)-mediated phosphorylation of sphingosine, itself derived 
from cell membrane sphingolipids (8, 9). S1P is an important player in cell death (10) and proliferation (11), 
with evidence that the balance between S1P and its pro-apoptotic precursors (sphingosine and ceramide) 
critically controls cell fate (12). Furthermore, S1P signalling is involved in cell adhesion and motility, smooth 
muscle contraction, and platelet aggregation (13). 
S1P and its 5 known receptors (S1P1-5) are expressed in several systems, including the vascular, 
immune, nervous, and reproductive systems (14). S1P1 receptors have been detected in blood vessels and 
mesenchymal cells around day 12 of embryonic development (15). Their genetic deletion leads to defective limb 
chondrocyte development, and embryonic lethality from defective vasculature. Limb defects occur both 
following non-specific deletion and in mice specifically lacking endothelial S1P1 receptors, and there is 
evidence that S1P1 receptors may play a role in chondrocyte organization. Indeed, by day 16 of murine 
embryogenesis, S1P1 receptor mRNA expression is abundant in bones undergoing ossification (16). As will be 
seen throughout this review, S1P receptors have also been identified in the key cells involved in bone 
remodelling and repair, including S1P1-3 receptors expressed in osteoblasts, and S1P1 and S1P2 receptors in 
osteoclast precursor cells. Under basal conditions, the expression of S1P4 and S1P5 receptors seems to be limited 
to hematopoietic and lymphatic tissues (S1P4) and the central nervous system (S1P5) (17) and there is currently 
little evidence that either subtype plays a direct role in bone remodelling or repair. Semi-quantitative RT-PCR 
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studies failed to detect mRNA for these two subtypes in primary rat osteoblasts (18), while they detected mRNA 
for all known S1P receptors except S1P5 in bone marrow-derived macrophages and differentiating osteoclasts 
(19). However, a more recent quantitative RT-PCR study found mainly S1P1, S1P2, and S1P3 receptor mRNA, 
with much lower levels of S1P4 receptor mRNA, and no detectable S1P5 receptor mRNA in primary osteoclasts 
or osteoblasts (20). Current pharmacological evidence for a lack of S1P4/5 receptor involvement should be 
interpreted with caution due to the poor characterization and/or selectivity of available drugs (see Table 1). 
Studies using novel agents specific for S1P4 and S1P5 receptors (21) are needed to rule out, or possibly uncover, 
a role of these subtype in bone (patho)physiology.  
The therapeutic potential of interfering with S1P signalling has mostly been explored in the immune 
(22), nervous (23), and cardiovascular systems (24). The function of S1P receptors in the immune system 
especially is increasingly better understood, with apparent roles in cell trafficking (25), allergic responses (26), 
and coagulation secondary to inflammatory conditions (27). The role of S1P in maintaining vascular integrity is 
also linked to inflammatory cell trafficking (28), suggesting that the effect of S1P on the immune and 
vascularization responses could contribute to bone repair, and could be exploited for therapeutic purposes in this 
context.  
This review will focus on the role of S1P in bone regeneration, teasing out its interaction with the 
various cellular components of bone repair. It will evaluate whether the manipulation of S1P signalling has been 
effective in cases of critical bone defects, bearing in mind the complexity of S1P signalling, and the uncertainty 
regarding the specificity of the pharmacological tools used in the studies in question (29). Table 1 lists the S1P 
receptor agonists and antagonists frequently mentioned in this review, with their presumed subtype 
selectivity/specificity. 
Other agents activating or blocking S1P receptors, or interfering with S1P metabolism have been 
described (30, 31). To the best of our knowledge, they have not yet been used to characterize the role of S1P 
signalling in bone biology and are therefore not listed here. 
 
2 Bone repair 
Bone is exceptionally proficient at self-repair, often able to avoid the formation of fibrous scar tissue in favour 
of complete regeneration (40). The cells responsible for bone development and repair are the same. Stem cells of 
mesenchymal origin are the source of bone forming osteoblasts and cartilage forming chondrocytes (41) 
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whereas haematopoietic stem cells are the source of the monocytes and macrophages that differentiate into 
multinucleated osteoclasts, responsible for bone resorption (42). These cells collaborate in the formation of 
functional bone through intramembranous and endochondral ossification (43). Intramembranous ossification 
(IO) involves the direct differentiation of mesenchymal stem cells into osteoblasts and the deposition of bone, as 
occurs during the formation of bones of the skull. Endochondral ossification (EO), typical of long bone 
formation, involves an intermediary step, the formation of chondrocytes, and the deposition of cartilage, which 
acts as a template for osteoblasts as cartilage is systematically replaced by bone (44).  
The process of bone repair echoes osteogenesis and resembles either EO or IO, depending on the size 
and location of the defect encountered. When the defect is sufficiently small and rigid, and adjacent bone 
cortices are in contact, deposition of bone may take place directly via IO, without intermediate cartilage 
formation. This direct, or primary, repair process requires the recruitment of osteoprogenitor cells, osteoclasts 
and undifferentiated mesenchymal stem cells to the fracture site. In contrast, indirect repair is similar to EO and 
involves the formation of a cartilaginous template (soft callus) that undergoes calcification into a hard callus and 
is eventually replaced by new woven bone (44). This process typically involves an acute inflammatory phase, 
which includes haematoma formation at the defect site, an early response by platelets, and neutrophils, followed 
soon after by monocytes and macrophages, resulting in thrombus formation, debris removal and the eventual 
formation of granulation tissue. Inflammation is continuously supported by positive feedback from the release of 
interleukins (primarily IL-1, and -6, along with -11, and -18) and tumor necrosis factor α (TNF-α) mainly in the 
first 24 hours after injury (45). Other important factors include platelet derived growth factor (PDGF) and 
macrophage colony-stimulating factor (M-CSF), which, together with stromal cell-derived factor 1 (SDF1, 
CXCL12) contribute to the recruitment of stem cells from the immediate bone environment and from the 
circulation (44, 45). These stem cells are essential for the next stage of regeneration, the formation of the soft 
callus. Hypoxic conditions in the haematoma may contribute to the promotion of chondrocyte differentiation 
from progenitor stem cells, and subsequent cartilage deposition (46, 47). Angiogenesis and blood vessel 
infiltration controlled by angiopoetin-1 and -2 and by vascular endothelial growth factor (VEGF) increase until 
hypoxic conditions begin to resolve (45). Improved circulation, as well as the activation of M-CSF, receptor 
activator of nuclear factor kappa B ligand (RANKL) and TNF-α, stimulate chondroclastogenesis and cartilage 
mineralization (48). The resolution of hypoxic conditions is followed by osteoblast proliferation and 
differentiation, leading to the deposition of woven bone. Cytokines such as transforming growth factors β2 and 
3 (TGF-β) and bone morphogenetic proteins (BMP) -2, -5, and -6 exert control over the healing process by 
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supporting continued proliferation, differentiation, and activity of osteoblasts, as well as the long term 
remodelling and restoration of woven bone into lamellar, functional bone (45, 49). The cell types and processes 
involved in bone repair are shown in Figure 1. 
 
The role of several mediators and signalling pathways in bone repair (e.g., BMPs, VEGF, Wnt and 
Notch pathways) and therapeutic attempts at harnessing them to improve bone repair have been the subject of 
various reviews (4, 41, 50-52). Less attention has been paid to the role of S1P signalling in bone disorders and 
repair (53). This review will therefore summarise the key findings in this field, with emphasis on the effects of 
S1P on the migration, differentiation and survival of the cellular components of bone repair and their respective 
precursors. In addition to the well-known role of S1P in vascularization and immune cell trafficking, these 
effects are likely to underlie any observed improvement in repair of bone defects following pharmacological 
intervention targeting S1P signalling. 
3 S1P effect on progenitor stem cells 
After injury, bone healing relies not only on differentiated bone cells but also on the recruitment of 
undifferentiated cells from bone and adjacent tissues. S1P regulates cell trafficking through surface receptors 
that respond to the S1P gradient between tissues (where S1P is found in nanomolar concentrations) and the 
blood (where it is found at micromolar concentrations), a gradient which may arise due to high levels of S1P 
degrading enzymes in the tissue compared to the blood (54). In general S1P functions as a chemoattractant for 
quiescent stem cell populations (55), and also participates in their differentiation into specialist bone forming 
and bone resorbing cells, as will be explored in more detail in the forthcoming sections.  
3.1 S1P and stem cell migration 
The balance between the major chemo-attractants CXCL12 (also known as SDF-1), predominantly found in 
bone marrow, and S1P, mainly found in the blood, dynamically regulates haematopoietic stem cell recruitment 
to the circulation versus their retention in the bone marrow. The principal chemoattractant retaining progenitor 
stem cells in a quiescent state in the bone marrow is CXCL12. Dissipating the S1P gradient between the blood 
and bone marrow by inhibiting S1P degradation in tissues or downregulating stem cell S1P1 receptors using 
fingolimod both reduce the number of circulating progenitor stem cells (56). The S1P3 receptor has been shown 
to have the reverse effect, whereby S1P3 agonism stimulates CXCL12-based retention of haematopoietic stem 
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cells within the bone marrow, and S1P3 antagonism contributes to increased stem cell egress (57). Stress, such 
as that occurring in a fractured bone, induces the downregulation of CXCL12 in the bone marrow and an 
increase in circulating S1P levels, leading to stem cell mobilization and migration into the blood stream (58). 
These observations support a role for S1P in the exit of cells from the bone marrow, a finding reminiscent of 
S1P-mediated lymphocyte egress from lymph nodes (22). Therefore, by manipulating S1P levels in the local 
environment of a tissue injury site, it may be possible to draw more of the local progenitor resources into the 
repair process. 
S1P-treated stromal cells show increased expression of extracellular matrix protease (e.g., MMP1) 
(59), which are important in breaking down collagen during the cell migration process (60). S1P also induces 
stromal cell migration and formation of capillary-like structures (59) and Rho-dependent formation of stress 
fibres, followed by lamellipodia and filopodia, in bone marrow derived cells. MMP or MEK1-ERK1/2 
inhibition reduces S1P-induced actin stress fibre formation, with no impact on lamellipodia or filopodia. MMP 
inhibition also interferes with S1P activation of RhoA and ERK, while Rho kinase blockage produces sustained 
S1P activation of ERK. This shows the intricate interplay downstream of S1P stimulation in the pathways 
involved in cell migration (61). 
Medium conditioned by RANKL-differentiated bone marrow cells contains S1P that stimulates 
chemotaxis of mesenchymal stem cells (MSC) (62). Two parallel signalling pathways seem to be involved in 
this MSC migratory response: S1P1 receptors activating the JAK/STAT pathway and S1P2 receptors activating 
the FAK/PI3K/AKT pathway (62). Contrasting with these findings, a recent study showed that S1P2 receptors 
played a critical role in the inhibition of MSC migration through ERK phosphorylation (63), an effect more in 
line with the more commonly observed inhibition of migration by S1P2 receptors (64). Confirming the effects of 
S1P signalling on the recruitment of endogenous stem cells, exposure of bone marrow derived MSCs to the S1P 
agonist fingolimod released from biodegradable polymer scaffolds enhanced MSC migration toward CXCL12 
(65), but the pharmacological profile of this response was not assessed. In these experiments fingolimod also led 
to cellular mineralization, an indicator of differentiation into the osteoblast lineage, and promoted 
vascularization (65).   
3.2 S1P and stem cell differentiation 
MSCs can differentiate into osteoblasts and adipocytes; commitment to one lineage inhibits commitment to the 
other due to the existence of negative feedback loops. S1P reduced adipogenic differentiation in MSCs (66) and 
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increased their differentiation into osteoblasts as shown by increases in alkaline phosphatase and osteocalcin 
mRNAs, and the appearance of calcified deposits (66). While the MSC cell line expressed both S1P1 and S1P2 
receptors, the inhibition of C/EBPβ expression by S1P was sensitive to pertussis toxin, suggesting that S1P1 
receptors played a key role (66). A recent study further defined the nature of the Wnt pathway involved in S1P-
induced osteogenic differentiation of MSCs, implicating the Wnt5a ligand and LRP5/6 receptor (67). In another 
study, S1P-functionalized titanium oxide coated stainless steel used as a growth substrate for human adipose 
derived stem cells also fostered their osteogenic differentiation (68). Both the S1P1/3 receptor antagonist 
VPC23019 and blocking of BMP6 with a neutralising antibody, polyclonal IgG reduced the mineralization 
response of human MSC to osteoclast-conditioned media, and similarly interferes with MSC migration. 
Indicating that osteoclasts and associated S1P release (among other osteoblast-osteoclast coupling factors) 
stimulate MSC differentiation and migration (69).  
4 S1P and osteoblasts 
4.1 Proliferative effect 
Short (10-45 min) but not protracted (24 hr) treatment with S1P induces ERK-dependent proliferation of both 
rat and human osteoblasts (70, 71). This time dependence has been tentatively explained by the possibility that 
S1P might first induce an early phase of cell growth, but, upon longer stimulation, lead to a phase of 
differentiation in which proliferation stops. Alternatively, the differential increase in the PKCα isoform 
following short- vs. long-term exposure to S1P might also have played a role (71). This possibility is supported 
by the observation that, in response to a 10-minute S1P stimulation, PKCα immunoreactivity was redistributed 
from the cytosol to the nucleus (72). Osteoblasts are known to express S1P1, S1P2 and S1P3 receptors (18-20), 
but none of the studies mentioned above addressed the identity of the receptor involved in the proliferation 
response; while pertussis toxin sensitivity pointed to an S1P1-mediated effect (71), the S1P concentration used 
(10 μM) was higher than usually needed to activate S1P receptors. A more recent study reported increased DNA 
synthesis at S1P concentrations of 1 µM (18); S1P induced activation of p42/44 MAP kinases, in a Gi- and 
calcium-dependent manner, but independently of PKC, and proliferation was observed in response to 24-hour 
S1P treatment. When the effects of S1P were studied in human primary osteoblastic cells and the human 
osteosarcomal cell lines, G292 and MG-63, 10 minute incubations with 10 nM S1P increased proliferation in a 
pertussis toxin-sensitive manner, while the effect of 24-hr incubation were less consistent. In G292 cells, this 
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longer exposure produced significant increases only with subnanomolar S1P, while higher doses had no effects; 
no proliferation was observed at any concentration in the other cell types (73). Both proliferation and apoptosis 
control the number of osteoblasts, and Gi proteins are not only involved in S1P-induced osteoblast proliferation 
but also in their survival. However, the role of PI3K appears to be restricted to the latter effect, since PI3K 
inhibition does not prevent the proliferative actions of S1P in osteoblastic cells (74). 
4.2 Osteoblast differentiation 
Differentiation of osteoblast precursors into mature osteoblasts is accompanied by an increase in SK 1 
expression and enzyme activity, decreased levels of S1P1 and S1P2 receptor proteins, and increased levels of 
S1P3 receptor proteins (75). Sphingosine kinase inhibitor (SKI-II), an anti-S1P antibody and the S1P1/3 receptor 
antagonist VPC23019 all reduce alkaline phosphatase activity, while blocking S1P1 receptors with W146, or 
S1P2 receptors with JTE013, has no effect (75). A similar pharmacological profile was observed with RUNX2 
expression (a key transcription factor associated with osteoblast differentiation), suggesting the existence of an 
autocrine SK1/S1P/S1P3 signalling pathway during osteoblastic differentiation (75).  
Other S1P receptors and signalling pathways may also mediate osteoblastogenesis. Activation of S1P 
receptors in C2C12 myoblasts enhanced BMP-2-induced expression markers of osteoblast differentiation (76). 
The expression of RUNX2 was likewise increased in the presence of S1P or fingolimod, as were Smad 
transcription factors and ERK1/2 (76). S1P and fingolimod also enhanced BMP-2-stimulated Smad1/5/8 
phosphorylation in C2C12 cells, and cell differentiation was sensitive to Pertussis toxin, to a MEK1/2 inhibitor, 
to the S1P1 receptor antagonist W146, and, to a smaller extent, to the S1P2 antagonist JTE013, whereas an S1P3 
antagonist (CAY10444) had no effect. A similar pharmacological profile was observed for the effects of S1P on 
other osteoblast-like cell lines (human SaOS-2 and murine MC3T3-E1). In these cells, S1P activated PI3K/Akt 
signalling, inhibiting GSK-3β, promoting nuclear translocation of β-catenin and expression of osteoprotegerin 
(that inhibits osteoclastogenesis by acting as a soluble decoy receptor for RANKL), and enhancing ALP activity 
(77). In a more recent study by the same group, S1P stimulation of Smad1/5/8 phosphorylation was attributed to 
S1P2-G12/13-RhoA activity, leading to the nuclear translocation of the Smad complex, up-regulation of RUNX2 
leading to increased ALP (78). Of note, this (77) and another study (19) found that S1P also increased RANKL 
mRNA in osteoblasts, but the OPG/RANKL ratio was higher after S1P treatment, which should lead to an 
overall inhibition of osteoclast maturation (77). Increased SK activity indeed reduces osteoclastogenesis in a 
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monoculture of osteoclast precursors; however, in an osteoblast/osteoclast co-culture system, which better 
reflects the reality of a healing bone, S1P stimulated osteoclastogenesis (19).   
As mentioned above, S1P seems to act as a coupling factor between osteoclasts and osteoblasts, and is 
referred to as a clastokine (79). Osteoclasts lacking the bone degrading enzyme cathepsin K show increased SK 
1 expression and culture media conditioned by these cells were shown to induce a larger increase in ALP and 
mineralized nodules in osteoblast cultures, due to their higher S1P content. This response was blocked by the 
S1P1/3 antagonist VPC23019, in agreement with the studies described above (80). 
4.3 Osteoblast precursor migration 
Together with its activity on their proliferation and differentiation (18, 70-78, 80), S1P also affects the migration 
of osteoblast precursors (81). Treatment of mouse primary pre-osteoblasts with S1P drives cells toward the bone 
surface environment (81). However, when precursors differentiate into mature osteoblasts, they become 
insensitive to S1P, although they retain their chemotaxis to PDGF (81). The response to S1P is not sensitive to 
pertussis toxin, suggesting that a subtype other than S1P1 is involved in the chemorepellent response to S1P. 
Indeed, expression studies and experiments with JTE-013 or with anti S1P2 siRNA point to a developmental 
stage specific role of S1P2 receptors. The chemorepellent effect of S1P2 receptors is typical of this subtype in 
various cell types, whereas S1P1 receptors are associated with chemotaxis to S1P in other cells important for 
bone repair: MSCs that give rise to cells of the osteoblast lineage (see (62) above), endothelial cells (82) or 
osteoclasts (see below). The lack of S1P1-mediated positive chemotactic response in osteoblasts, despite high 
S1P1 expression levels in these cells, is therefore unusual.  
4.4 Other effect of S1P signalling in osteoblasts 
S1P has long been known to release calcium from intracellular stores in pre-osteoblasts (83, 84). Because of 
calcium’s central role in cell signalling, it is therefore not surprising that S1P is implicated in many osteoblast 
functions. Indeed, S1P stimulates IL-6 synthesis in these cells in a p42/p44 MAPK dependent manner (85), 
induces the synthesis of heat-shock protein 27 (HSP27) via p38 activation (86), and enhances PGF2α-induced 
phosphoinositide hydrolysis by phospholipase C through p38 MAPK (87, 88).  
Administration of epidermal growth factor, a known mitogenic factor for osteoblasts, increased S1P 
levels which coincided with increased cell proliferation (89). There is also evidence for the involvement of S1P 
signalling in calcitonin activity (90). Calcitonin is an anti-resorptive hormone previously indicated in 
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osteoporosis, however it may also influence bone formation through its interactions in S1P signalling. By 
decreasing the expression of the S1P transporter Spns2 in osteoclasts (20), limiting the cross-talk between 
osteoclasts and osteoblasts, and so also limiting S1P- or fingolimod-induced bone formation by osteoblasts 
which was found to be mediated by S1P3 receptors (20).  
S1P may also influence mature osteoblasts following their entombing as osteocytes in the bone matrix, 
as S1P signalling via the S1P2 receptor has been shown to affect  mechanotransduction in an osteocyte-like cell 
line (MLOY4) (91). 
5 S1P and osteoclasts 
Osteoclasts are multinucleated, resorptive cells whose development is influenced by osteoblast lineage cells 
(92). Osteoclasts are responsible for the continuous remodelling of bone, working in tandem with bone forming 
osteoblasts (93). The coupling between osteoclasts and osteoblasts in osteoclastogenesis is a clear example of 
the functional relationship between the two cell populations, and S1P seems to play a role in the crosstalk 
between these two cell populations and their differentiation, as represented in Figure 2. 
5.1 S1P and osteoclast recruitment   
S1P can regulate the migration of osteoclast precursors both in vitro and in vivo. Bone marrow derived 
monocytes (an in vitro model of osteoclast precursors) express both S1P1 and S1P2 receptors.  Upon exposure to 
RANKL, these cells differentiate into osteoclast-like cells and show decreased S1P1 expression, with 
concomitant loss of chemotactic response to S1P (94). Knockout mice with specific S1P1 deletion in the 
monocyte lineage are osteoporotic, a phenotype that has been attributed to the loss of S1P1 control of osteoclast 
precursor migration and increased residency time at the bone surface (94). The potential therapeutic significance 
of these findings was confirmed in an ovariectomy-induced osteoporosis model: fingolimod prevented bone loss 
in ovariectomized mice, but had no effects in sham-operated mice. This effect was due to a reduction of 
osteoclast deposition onto bone surfaces (94). In a rat model of periodontitis, fingolimod was found to reduce 
the number of osteoclast precursors and mature osteoclasts at the defect site, and increase the number of 
precursors in blood, an effect attributed to S1P1-induced positive chemotaxis (95).   
S1P2 receptor deficient mice show higher bone density than control mice (96), and S1P2 receptors seem 
to antagonize the effect of S1P1 receptors on osteoclast precursor migration. Positive and negative chemotaxis 
are attributed to S1P1-mediated activation of Rac via Gi, and S1P2-mediated activation of Rho via G12/13, 
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respectively (96). An in vitro migration assay of osteoclast precursors expressing both receptors subtypes 
showed that lower S1P concentrations stimulate positive chemotaxis, while higher concentrations stimulate 
negative chemotaxis, or chemorepulsion, suggesting that S1P2 receptors may only be active at high S1P 
concentrations. S1P1-deficient osteoclast precursor cells show very little motility, while S1P2-deficient cells 
showed positive chemotaxis, even at high S1P concentration (96). Intravital imaging confirmed the chemotactic 
effect of S1P2 by showing that the antagonist JTE013 mobilised a small subset of monocytic lineage cells from 
the calvarium and led them to enter the blood circulation (96).  
5.2 Therapeutic manipulation of osteoclast trafficking 
While approved or investigational anti-resorptive agents (e.g., bisphosphonate or cathepsin K inhibitors) target 
mature osteoclasts, manipulating osteoclast precursors would provide a novel therapeutic modality for bone loss. 
Indeed, the opposing roles of S1P1 and S1P2 receptors on precursor recruitment might underlie therapeutic 
interventions (i.e., activation of S1P1 or blockade of S1P2 receptors) that could prevent bone loss in conditions 
associated with inflammation and/or remodelling imbalance. This potential was ascertained using murine 
models of rheumatoid arthritis (in which fingolimod was as effective as prednisolone) and osteoporosis 
(fingolimod improved bone loss, but prednisolone had no effect) (97). In a model of periodontitis, a bacteria-
driven inflammatory bone loss disease, fingolimod inhibited osteoclastogenesis and pro-inflammatory cytokines 
involved in osteoclast precursor recruitment (98).  
Vitamin D analogues are used for the treatment of osteoporosis, but their mechanism of action is not 
completely clear.  For instance, in vitro calcitriol increased RANKL expression in bone marrow stromal cells, 
thereby activating osteoclasts and bone resorption (99). A recent study showed that vitamin D’s effect on 
osteoclast precursor migration might underlie its anti-resorptive activity. Indeed, calcitriol and its analogue 
eldecalcitol were found to uniquely reduce S1P2 receptor expression in monocytic osteoclast precursors (99), 
while circulating monocytes expressed fewer S1P2 receptors in mice treated with calcitriol or eldecalcitol, and 
monocyte mobility was observed to increase in eldecalcitol-treated mice after treatment with JTE013 (99).  
Whereas vitamin D analogues reduce S1P2 receptor expression, a recent study showed that the 
inflammatory cytokine IL-6 induced S1P2 mRNA, but not S1P1 mRNA expression in osteoclast precursor cells 
(100). This effect was associated with a decrease in S1P-induced chemotaxis and an increased number of 
precursors in tibial bone marrow.  Systemic treatment with an anti-IL-6 receptor antibody prevented bone loss 
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and decreased the number of precursors in tibial bone marrow via S1P2 receptor down-regulation (100), further 
validating the potential therapeutic value of S1P2 antagonists. 
The following table summarises some of the effects of S1P receptors on the cellular components of 
bone repair. 
6 S1P in the vasculature and the role of angiogenesis 
The repair of cranial bone defects by scaffold-mediated delivery of S1P agents involves not only the recruitment 
of bone cell progenitors, but also production of new vessels in the defect space (105, 106). Hence, while the 
previous sections focused on bone cells and their interactions, it is important to remember that bones are highly 
vascularized, perfused by up to 20ml of blood/100g of bone every minute (107). Blood vessels are not only an 
essential conduit for blood, providing minerals, nutrients, growth factors and osteoprogenitors, but the 
endothelium also acts as a paracrine and endocrine organ involved in growth factor production, coagulation, 
inflammation and the immune response (108). Fracture disrupts the bone’s vasculature, leading to hypoxia and 
necrosis of adjacent tissue. Reestablishment of the circulation and neovascularization in the tissue formed in 
response to injury are critical for successful fracture healing (109). Unfortunately, bone repair strategies based 
on bone grafts or scaffolds have so far shown limited success due in part to the lack sufficient blood vessel 
supply during the early stages of the repair process (20, 21). 
There are three main mechanisms for producing new vessels (110). Vasculogenesis refers to the de novo 
generation of blood vessels that occurs for instance during embryogenesis. It differs from angiogenesis, which is 
the generation of new vessels from pre-existing ones. Angiogenesis occurs during physiological (e.g., wound 
healing or menstrual cycle) or pathological processes (e.g., neovascular disorders, rheumatoid arthritis and 
cancer). It can result from the formation of a new vessel branching off an existing vessel (sprouting 
angiogenesis) or from the splitting of a blood vessel into two or more vessels (intussusceptive angiogenesis). 
Finally, arteriogenesis is the remodelling of an existing artery to increase its luminal diameter. While 
arteriogenesis, and possibly angiogenesis (111-113), occurs in response to physical forces such as increased 
blood flow, angiogenesis is initiated in poorly perfused tissues when low oxygen levels lead to increased levels 
of the transcription factor Hypoxia-Inducible Factor (HIF)-1α in parenchymal cells.  
VEGF is the main HIF-1α–dependent pro-angiogenic factor, and inhibiting VEGF signalling impairs healing of 
femoral fractures and cortical bone defects in mice (114). Although VEGF is the archetypical pro-angiogenic 
factor, it promotes by itself the formation of immature and leaky vessels (115). In contrast, angiopoetin-1 
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produces vessels that are resistant to leak (116), suggesting that different vascular growth factors play 
complementary and coordinated roles in new vessel formation, and that therapeutic strategies aimed at 
promoting angiogenesis should target more than one mediator.  Indeed, when surgically implanted in the ear of 
mice, chemically modified hyaluronan hydrogels pre-loaded with both VEGF and angiopoetin-1 promote a 
larger angiogenic response than delivery of single growth factors (117).  More recently, sequential delivery of 
VEGF and S1P using a porous hollow fibre in a skin Matrigel plug assay was shown to lead to more endothelial 
cell recruitment and a higher maturation index than single factor delivery, reverse sequential delivery or even 
co-delivery (118). The concept that temporal control of growth factor release produces more mature new 
vessels, able to integrate with the existing vasculature, was validated in similar experiments using Basic 
Fibroblast Growth Factor and Platelet-Derived Growth Factor (119). 
These sequential release experiments were conducted over the course of a week, but the bone repair process 
takes months. Scaffold-mediated delivery of a low molecular weight, more lipophilic factor such as an S1P 
agent might be preferable to the delivery of recombinant proteins.  The role of S1P in the vasculature and new 
vessel formation is well documented and has been the subject of numerous reviews (120-122). Endothelial cells 
express the same S1P receptor subtypes as intrinsic bone cells (S1P1>S1P2≈S1P3); these receptors mediate 
generally similar cellular responses (proliferation, differentiation and migration), in addition to effects more 
specific to endothelial cells (modulation of cell adhesion and of the inflammatory/immune response). 
S1P seems to play a key role in both vasculogenesis and angiogenesis. In a mouse hind limb ischemia model, 
S1P stimulates angiogenesis (123), while postischemic blood flow recovery and angiogenesis are accelerated in 
transgenic mice overexpressing SK1 (124). At variance with the effects of VEGF however, the angiogenic 
response to S1P is not associated with increased vascular permeability in the ischemic limb, and many studies 
have shown that S1P actually enhances endothelial barrier integrity (120). In fact, in this model, S1P-containing 
Poly(lactic-co-glycolic-acid) (PLGA) microparticles not only stimulated post-ischemic angiogenesis at 28 days 
but also blocked edema induced when VEGF was co-administered (125). The effects of S1P1 and S1P3 receptors 
on adherens junctions in endothelial cells were documented soon after the identification of these receptors (126). 
While S1P1 and S1P3 receptors strengthen the formation of endothelial cell junctions (28, 127-129), S1P2 
receptors increase vascular permeability in vitro via disruption of adherens junctions (130, 131). In vivo, S1P1 
receptor activation inhibit VEGF-induced vascular leakage in skin capillaries (132), whereas S1P1 receptor 
antagonists have shown that they induce capillary leakage in the lung, kidney, skin, and intestine (133-135).  
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S1P1 receptors promote vascular stabilization by regulating the interactions between endothelial and mural cells 
during the maturation process (136, 137), and, in apparent contradiction with their pro-angiogenic effects 
mentioned above, S1P1 receptors were recently shown to inhibit sprouting angiogenesis during vascular 
development (138), by stabilizing VE-cadherin at endothelial junctions and inhibiting VEGFR2 (111, 112), 
suggesting the existence of an alternative mechanism that helps stabilize the newly formed vascular network and 
improves its barrier function. 
These data showing that S1P plays a role both at the early stages of angiogenesis and at the stage of new vessel 
stabilization, taken together with the effects of this lipid on bone cells, suggest that scaffold-mediated delivery 
of S1P (most likely S1P1) agonists might promote bone repair via pleiotropic and possible synergistic 
mechanisms. 
7 Current efforts in S1P delivery 
The importance of S1P as a chemoattractant, and in coupling the activity of osteoblasts and osteoclasts suggests 
it could be utilized systemically in bone repair, and in disorders such as osteoporosis (53). However, a study of 
daily subcutaneous fingolimod (6mg/kg) did not lead to any improvement in fracture healing of a murine 
femoral defect (139), indicating that a more localised approach of delivering S1P and related analogue, may lead 
to more promising results. 
Local administration of S1P has typically involved the use of scaffolds, which often have the dual role of acting 
as drug delivery device, and mimicking native tissue to elicit functional tissue development. Hence a range of 
biocompatible materials, including natural polymers (collagen, chitosan, silk),  synthetic organic polymers 
PLGA and poly-ε-caprolactone [PCL]) and inorganic materials (ceramics and glasses) have been investigated to 
fabricate scaffolds that are conducive to tissue regeneration, and allow temporal control over the release of 
therapeutic cargoes (140). Biodegradable PLGA is among the commonest copolymers investigated (141) and 
has been used to control the release of S1P (105) and fingolimod (142), resulting in increased new bone 
formation post-implantation in a rat cranial defect model, an effect that was attributed to increased development 
of vasculature and the possible dose-dependent initiation of bone progenitor cell migration towards the defect 
site (142). The underlying mechanism was probed in a similar study investigating the delivery of S1P agonists 
and antagonists (S1P, fingolimod or VPC01091) from PLGA scaffold implants in a rat cranial defect model 
(106). Although S1P is subject to much more rapid in vivo degradation than fingolimod, scaffolds loaded with 
either agonist were equally effective in generating new bone over 6 weeks, while VPC01091-loaded scaffolds 
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did not differ from unloaded controls (106). This study suggests that sustained release from scaffolds may offset 
the challenges of employing therapeutic cargoes (e.g. S1P) with short half-lives, and that S1P3 receptors 
synergize with S1P1 receptors to influence the various processes underlying repair (i.e., vascular remodelling, 
cell proliferation and migration, inflammation), albeit to differing extents. fingolimod has been incorporated into 
electrospun nanofibers composed of PLGA and biodegradable PCL and showed significant improvement in 
defect healing and vascularization in a rat critical mandibular defect (143). These fingolimod-loaded nanofibers 
increased neovascularization and enhanced the proportion of macrophages with an anti-inflammatory phenotype 
(M2) (143), a cell population that is also known to play an important role in tissue repair (144), and had been 
previously shown to be selectively attracted by fingolimod (145). A similar result of anti-inflammatory 
macrophage stimulation was found in another study using a PLGA coated allograft (146), and whilst SEW2871 
was also observed to stimulate macrophage recruitment, details regarding phenotype were not reported (147). 
An electrospun amphiphilic copolymer was developed to act as a carrier for S1P to promote vascularization in 
tissue repair applications, the amphiphilic nature of the copolymer was anticipated to mimic the binding of S1P 
to apolipoprotein M. S1P was first applied directly to endothelial cells (HUVEC), and showed pro-angiogenic 
effects in a tube formation assay. Tube length and uniformity were then improved when S1P was administered 
as part of the amphiphilic scaffold, additional evidence of new vessel formation was shown in a 3-day 
chorioallantoic membrane assay (148). 
Whether small molecule delivery alone will achieve sufficient and effective bone repair remains to be 
established, but it is worth noting that fingolimod PLGA microspheres in a chitosan gel improved bone 
regeneration in a rat cranial defect study, with no substantial improvement upon addition of BMP-2 to 
fingolimod-loaded microspheres (65), despite fingolimod being known to enhance BMP-2 mediated osteoblast 
differentiation in vitro (76). Conversely, SEW2871 alone failed to improve bone regeneration, but co-
administration with platelet rich plasma improved the latter’s performance, by enhancing macrophage 
recruitment and cell debris clearance (149). Combining S1P with low-cost, biocompatible, biodegradable 
polymers represents an enticing alternative prospect for current bone graft treatments. Unfortunately, results to 
date still show most polymeric biomaterials cannot match the efficacy of bone grafts, because they lack both the 
osteogenic and osteoinductive properties that make grafts so successful. Consequently, bioactive polymer-graft 
composites are a potential solution to recapitulate mechanical and biological properties of host tissue in an effort 
to repair critical-sized defects. In one case, fingolimod elution from a PLGA-coated devitalized-bone allograft in 
a critical rat tibial defect improved elastic modulus and ultimate compressive strength of the bone, outcomes 
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attributed to evidence of enhanced active remodelling at the defect site (150). The same procedure was 
investigated further, and similarly attributed tissue regeneration to improved vascularization, while also 
presenting a more detailed discussion of the role of bone marrow derived cells in immune modulation (146). 
Another PLGA coated allograft delivery system for fingolimod showed a dose-dependent increase in bone 
volume in a cranial defect model at 2 and 4 weeks. Although differences in bone volumes were no longer 
significant at 8 weeks, fingolimod still enhanced host-graft integration at this time point (151). Notably, direct 
adsorption of fingolimod onto implanted allograft improved bone deposition and vascularisation (152). 
Predictably, this method produced higher local concentrations of fingolimod, but lower increases in bone 
density compared to polymer based delivery discussed above (151, 152). 
8 Conclusion 
Although the role of S1P in bone biology has been the focus of much less research than its role in the 
cardiovascular and immune systems, it is becoming clear that this lipid influences many of the functions, 
pathways and cell types that play a key role in bone repair. Indeed, S1P has a well-established role in promoting 
angiogenesis (14, 105, 148, 153, 154), but is also implicated in many other bone related processes including 
stem cell recruitment (59, 62, 155) and subsequent differentiation (66). S1P stimulates the differentiation and 
survival of osteoblasts (76, 77), and contributes to their intricate coupling with osteoclasts (19). S1P is not only 
a key factor in its own right, it also seems to mediate the functions of critical bone growth factors, such as BMPs 
(69, 76). Although the use of growth factors for bone repair has been widely explored, some issues remain, such 
as those related to supra-physiologic doses (156), short half-lives (157), an inability to maintain osteogenicity 
due to slow vascular integration of grafts (2), not to mention high costs (158). As summarized in earlier sections, 
various groups have therefore begun to explore the use of non peptidic agents, such as S1P and analogues, to 
promote bone repair in vivo, with generally promising results. Remaining issues regarding pleiotropic activity 
(159), solubility (147) and the need to maintain local concentrations over a number of weeks (159) may be 
addressed by using more specific agents and/or novel delivery options. A number of such delivery methods have 
been studied in the field of bone repair to enhance delivery of growth factors (158, 160, 161), small molecule 
drugs, and stem cell therapies (48, 162, 163). They have generally involved biomaterials for controlled release 
of drugs including biocompatible, biodegradable polymers, and bio-ceramics (4, 163) and the use of high 
affinity delivery systems, which have led to reductions in required doses (5).  
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The use of S1P agents for bone repair is likely to be greatly accelerated by the much more active 
translational and clinical research of the role of S1P signalling in other fields, such as inflammation or cancer. 
The number of active clinical trials involving S1P receptor ligands in inflammatory conditions ranges from 2 
and 3% of trials for inflammatory bowel disease and psoriasis, up to 32% of all trials for new multiple sclerosis 
therapies (164). S1P1 receptors have been the focus of most research in this field, as evidenced by the great 
emphasis placed on the development of agents such as ponesimod, siponimod, and ozanimod, with improved 
specificity compared to fingolimod. Whilst other possible targets, such as S1P lyase inhibition have been less 
well investigated (165). In the field of bone repair, further basic and translational research will be needed to 
better define which S1P metabolic enzymes or receptors should be targeted, when and for what duration, and 
whether an agonist or an antagonist would be preferable. The latter issue is particularly critical considering that 
S1P1 receptor agonists seem to exert their action as functional antagonists, with S1P1 agonists and antagonists 
showing similar therapeutic effects (166). Furthermore, some of the work quoted in this review has been based 
on qualitative or semi-quantitative data, and the pharmacological profile of the response was sometimes unclear, 
either due to incomplete dose response studies, or the use of agents with questionable specificity (29, 35) . 
To conclude, the manipulation of S1P signalling using systemic administration of therapeutic agents 
seems promising for the management of inflammatory or hormonally-related bone loss, as S1P agents can be 
used to affect osteoblast/osteoclast coupling, the unbalancing of which manifests as conditions such as 
osteoporosis. In contrast, local administration of S1P agents has shown more compelling results in bone defect 
studies, and so improving local delivery of these agents will be key to optimising their regenerative potential. 
Critically, this may be achieved by not only increasing the recruitment of osteogenic cell precursors but also by 
inducing and supporting vascularization and modulating the immune response; S1P agents may be unique in 
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Fig. 1 (a) A simplified representation of the lineages of the cells involved in bone repair. Mesenchymal stem cells (MSC) 
differentiate into the major bone and cartilage forming cells, osteoblasts and chondrocytes (later replaced by osteoblasts), 
depending on whether ossification occurs through the intramembranous or endochondral pathways. Haematopoietic stem 
cells (HSC) differentiate into bone resorbing osteoclasts through the myeloid pathway. (b) Process of bone repair divided 
into 4 phases: inflammatory, soft callus, hard callus, and remodelling. Briefly, an early inflammatory response results in the 
removal of debris and the eventual recruitment of mesenchymal stem cells, initiating the soft callus phase and cartilage 
deposition. Improving vascularization leads to cartilage mineralization and deposition of bone, which is then slowly 
remodelled, restoring function. 
Fig. 2 Simplified illustration of the effects of S1P and its receptors on osteoblasts, osteoclasts, their respective precursors, 
and the role of S1P in osteoblast-osteoclast coupling. The involvement of the 3 major S1P receptor subtypes (red: S1P1, 
green: S1P2, orange: S1P3) in particular responses is indicated by different arrow shapes. Briefly, osteoclast and osteoblast 
precursor migration is influenced by S1P1-mediated chemoattraction and S1P2-mediated chemorepulsion in response to the 
the S1P concentration gradient (larger quantities of S1P are generated in serum mainly by red blood cells and endothelial 
cells, while lower S1P concentrations predominate in tissue compartments, such as bone). S1P, produced locally by 
osteoclasts or osteoclast precursors (20, 69, 80), directly stimulates the proliferation of osteoblast precursors and their 
differentiation into mature osteoblasts, while increasing RANKL mRNA in osteoblasts, indirectly stimulating osteoclast 













Table 1. List of S1P associated agents mentioned in the review. Of note, many of these agents only show subtype selectivity 
with a narrow range of concentrations, and have known non S1P receptor targets (for review see ((29))). 
AGENT SELECTIVITY/SPECIFICITY NOTES 
S1P S1P1-5 Agonist Endogenous agonist 
FINGOLIMOD Activates all S1P subtypes except 
S1P2, although recent evidence 
suggests S1P2 might also be a 
target (32). 
Fingolimod is a prodrug (activated by sphingosine 
kinase 2). Phosphorylated fingolimod is likely to act 
as a functional antagonist of S1P1 in its approved 
therapeutic role, as it rapidly downregulates S1P1 
receptors. The extent and the kinetics of fingolimod-
induced receptor internalization and of their recycling 
to the cell membrane seem to differ between various 
S1P receptor subtypes. Furthermore, the extent of 
receptor downregulation may also depend on 
fingolimod concentration, the concentration of 
endogenous S1P and the level of S1P receptor 
expression, possibly explaining why the functional 
effects of fingolimod in various systems can either 
resemble the effects of agonists or of antagonists 
(30). 
It is also a potent protein phosphatase 2A (PP2A)–
activating drug. Effects of sphingosine kinases and 
S1P lyase have also been shown. 
SEW2871 S1P1 Agonist First described S1P1-selective agonist. At variance 
with fingolimod, it demonstrates S1P1 agonist 
activity without long-term decrease in surface 
receptor expression (33). It is 10 to 50 times less 
potent than CYM5442 and poorly water-soluble (34). 
JTE013 S1P2 Antagonist Most commonly used S1P2 receptor antagonist, but 
its selectivity is questionable (35). 
32 
 
VPC23019 S1P1, S1P3 Antagonist pKB values of 7.5 and 6.0 for S1P1 and S1P3 
receptors, respectively (36). 
VPC01091 S1P1 partial agonist, S1P3 
antagonist 
The 1R,3S diastereomer is a conformationally 
constrained fingolimod analogue activated by 
sphingosine kinase 2 (37). 
W146 S1P1 Antagonist W146 is an antagonist, but its in vivo effect often 
mimic those of S1P receptor agonists (38). 
CAY10444 S1P3 Antagonist Also known as BML-241. Low potency and aqueous 
solubility agent. May also non-selectively inhibit 





Table 2. Cell types involved in bone regeneration and some S1P receptor related effects. 
 















Murine long bone 












MC3T3-E1 cell line, treated 
with 1-30µM S1P, media 
contained 0.01% bovine 
serum albumin 
↑IL-6 (85)  
S1P, various 
doses ranging 












Human osteoblast explant 
(71-73), Foetal rat  
osteoblasts (18, 70, 74), 





 S1P (100nM) 








MC3T3-E1 cell line, 
migration assay for PDGF 
and S1P pre-and post-
differentiation 
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in osteoblast differentiation 
media, contained 10% serum 













C2C12 murine osteoblast 
precursor cultured in media 
containing 10% serum. 
S1P and fingolimod used 
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Osteoclast from minced 
rabbit bones incubated on 
dentine slices. Treated for 16 
hours with S1P in media 
containing 10% serum 
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Cells cultured in media 
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use of JTE013 
3mg/Kg 
 
In vitro and in vivo 
investigation of the role of 































effect on S1P 
(10-6M) 





Monocytoid cell line 
migration assay 
 
















Murine osteoclast precursors 
cultured in media containing 
fatty-acid free bovine serum 
albumin, migration assay. 
In vivo arthritis model 
↑S1P2 Receptor 
expression  






S1P (1µM) No receptors 
were 
investigated 
Murine bone marrow 
stromal cells cultured in 
10% inactivated serum 
↑Stress fibre formation 
↑Migration 
(61)  













Human mesenchymal stem 
cells cultured in media 












Human bone marrow 
derived MSCs, cultured in 
↑Migration  


























C3H10T1/2 murine MSCs 
incubated with S1P for 15 
minutes to 24 hours. Media 















changes in gene 
expression 
Human adipose derived stem 
cells cultured on titanium 
oxide coated stainless steel 
doped in S1P, cells were 




↑Expression of S1P1 
and S1P2 at 80mg/mL 
↑Expression of S1P2 












Bovine and human cartilage 
explants (monolayer 



























Treated following serum 
starving (0.5% serum) 











MLO-Y4 cell line, 
oscillatory fluid flow, 
JTE013 
↑PGE2 release 
↓RANKL/OPG 
(91) 
 
 
